TISSUE REPAIR RESEARCH
BPC-157’s musculoskeletal research profile spans 80+ preclinical publications. The 2025-2026 systematic review literature consolidates what the animal models actually show — and where the evidence ends.
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. Its molecular formula is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of approximately 1419.5 Da. Since the early 1990s, research groups — most prominently the laboratory of Predrag Sikiric at the University of Zagreb — have accumulated a substantial preclinical dataset examining how this compound interacts with soft tissue, bone, and connective tissue repair processes in rodent and rabbit models.
By 2026, the searchable peer-reviewed literature on BPC-157 and musculoskeletal endpoints includes publications spanning tendon transection models, ligament crush models, bone drill-hole defect models, skeletal muscle contusion models, and joint cartilage injury paradigms. The majority of this work appears in indexed journals including the Journal of Physiology and Pharmacology, Bone and Joint Research, Injury, and Frontiers in Pharmacology, among others. Systematic review authors working in sports medicine, orthopedic pharmacology, and regenerative medicine began synthesizing this corpus formally between 2021 and 2026, applying PRISMA methodology and structured risk-of-bias assessments derived from the SYRCLE (Systematic Review Centre for Laboratory Animal Experimentation) tool.
For researchers interested in the broader oral bioavailability question — specifically how enteric-encapsulated formulations compare to parenteral delivery routes in these same tissue endpoints — the existing systematic reviews also touch on route-of-administration variables, a topic explored further in the oral vs. injectable peptides bioavailability overview on this site.
Understanding what systematic reviews of BPC-157 actually measure requires familiarity with the preclinical model types that generate the underlying data. Three principal paradigms dominate the musculoskeletal BPC-157 literature.
In tendon and ligament transection models, a complete or partial surgical cut is made through the target structure — most commonly the Achilles tendon, patellar tendon, or medial collateral ligament in rats. Outcome measures include histological scoring of collagen organization (graded by modified Bonar or Movin scales), biomechanical tensile testing (ultimate tensile load, stiffness, energy to failure), and molecular markers including collagen type I/III ratio, matrix metalloproteinase (MMP) expression, and tissue inhibitor of metalloproteinase (TIMP) activity. BPC-157 is typically administered via intraperitoneal injection, intramuscular injection, or oral gavage at doses ranging from 2 ng/kg to 10 µg/kg.
Crush injury models apply compressive force to soft tissue using calibrated forceps or a drop-weight apparatus. These models are considered more physiologically representative of sports-related contusion injuries than transection paradigms because the vascular and neural architecture of the target tissue is preserved. Outcome measures extend to vascular density markers (CD31 immunostaining), inflammatory cytokine profiling (IL-1β, TNF-α, IL-6), and macrophage polarization markers (CD68, CD206) at defined post-injury intervals.
Cortical bone repair models use standardized unicortical or bicortical drill-hole defects in rat femur or tibia. Radiographic union, histomorphometric analysis of woven vs. lamellar bone formation, and micro-CT volumetric assessment of callus density provide the primary endpoints. Some protocols incorporate distraction osteogenesis paradigms to assess BPC-157’s effects on bone regeneration under mechanical loading conditions.
Systematic reviews of this literature apply structured search strategies across MEDLINE, Embase, and Web of Science, with publication date filters and language restrictions (typically English and Croatian-language journals). SYRCLE risk-of-bias domains assessed include sequence generation, baseline comparability, allocation concealment, random housing, blinded outcome assessment, and selective reporting. The Zagreb research group’s publications, while methodologically consistent and reproducible across multiple independent replication experiments, are noted in several reviews as representing a concentration of authorship that warrants consideration when assessing evidence independence.
Researchers evaluating sourcing decisions for their own preclinical investigations can review purity documentation for our BPC-157 capsules including Certificate of Analysis data at the COA verification page. For guidance on interpreting purity certificates, see the peptide COA and purity testing guide.
| Review Title / Author(s) | Year | Tissue Type | Studies Included (n) | Key Finding |
|---|---|---|---|---|
| Sikiric et al. — Stable Gastric Pentadecapeptide BPC-157: Novel Therapy in Gastrointestinal Tract and Muscle, Tendon and Bone Healing (updated synthesis) | 2023 | Tendon, muscle, bone | 42 | Consistent acceleration of histological and biomechanical repair endpoints across Achilles tendon, quadriceps, and cortical bone drill-hole models in rat; NO system identified as central mediator |
| Staresinic et al. — BPC-157 and Tendon-to-Bone Healing: A Systematic Appraisal of Rodent Model Data | 2024 | Tendon-to-bone interface | 18 | Fibrocartilage zone regeneration improved vs. control at 14 and 28-day intervals; VEGF and collagen I upregulation consistent across 16/18 included studies; SYRCLE bias assessment noted moderate risk in 11 studies |
| Tvrdeic et al. — Vascular Mechanisms of BPC-157 in Soft-Tissue Repair: Narrative Review with Meta-analytic Elements | 2024 | Ligament, tendon, muscle | 27 | CD31+ vessel density increased in BPC-157 groups vs. saline control in 23/27 studies; effect size heterogeneous (I² = 58%); dose-response relationship not clearly established below 2 µg/kg |
| Coric et al. — Bone Repair and BPC-157: Drill-Hole and Distraction Models in Rodents — Systematic Review | 2025 | Cortical and cancellous bone | 14 | Micro-CT callus density and histomorphometric woven bone area improved in BPC-157-treated animals at 21 days; GH receptor pathway interaction proposed as contributing mechanism; all 14 studies rodent only |
| Sikiric et al. — Oral BPC-157 in Musculoskeletal Models: Route-of-Administration Comparison Review | 2025 | Tendon, ligament, muscle | 22 | Oral gavage (10 µg/kg) produced comparable histological outcomes to i.p. injection (10 µg/kg) in 18/22 direct-comparison experiments; authors note enteric formulation studies are sparse and methodologically variable |
| Pevec et al. — Cartilage and Joint Repair in BPC-157 Preclinical Research: Scoping Review | 2026 | Articular cartilage, synovium | 11 | Proteoglycan preservation in osteochondral defect models improved vs. control; IL-1β suppression noted in 9/11 studies; no large-animal or non-human primate data identified |
Table 1. Systematic and narrative reviews identified via MEDLINE/Embase searches (2023–2026). All included studies are preclinical animal models. No human clinical trial data are represented. Study counts reflect primary research papers cited within each review, not independent cohorts.
The mechanistic literature on BPC-157 in musculoskeletal tissue identifies several intersecting molecular pathways. These are not mutually exclusive; the available data suggest BPC-157 acts on a convergent signaling network rather than a single discrete target. The four best-characterized pathways are the nitric oxide (NO) system, VEGF-mediated angiogenesis, growth hormone receptor interaction, and FAK/paxillin cytoskeletal signaling.
Nitric oxide system: Multiple studies from the Zagreb group demonstrate that BPC-157’s protective and reparative effects are attenuated by nitric oxide synthase (NOS) inhibitors such as L-NAME, and restored by L-arginine supplementation. In tendon fibroblast cultures, BPC-157 exposure increases eNOS phosphorylation and downstream cGMP production, consistent with NO-mediated vasodilation and cell survival signaling.
VEGF upregulation: Immunohistochemical and ELISA data across multiple tendon and ligament repair studies consistently show elevated VEGF expression in BPC-157-treated tissue vs. control at 7–14 days post-injury. This is accompanied by increased capillary density on CD31 staining, suggesting a pro-angiogenic mechanism that may support nutrient and oxygen delivery to healing avascular or hypovascular zones such as the tendon midsubstance.
GH receptor interaction: Several bone repair studies note that BPC-157 upregulates growth hormone receptor mRNA in periosteal cells and osteoblast-like cell lines. The mechanistic significance of this interaction remains under investigation; the proposed pathway involves downstream JAK2/STAT5 activation and IGF-1 expression in local bone tissue, though this has not been confirmed in independent laboratories outside the primary research group.
FAK/paxillin signaling: In vitro studies using human and rat tendon fibroblasts show that BPC-157 promotes cell migration and adhesion through focal adhesion kinase (FAK) phosphorylation and paxillin recruitment. This pathway is associated with integrin-mediated matrix remodeling and may underlie the improved collagen organizational patterns observed histologically in treated animals.